Safety Profile of Desmopressin Tablet for Enuresis in a Prospective Study

Advances in Therapy

Volumn 31, Issue 12, 2014, Pages 1306-1316

  Van Herzeele, Charlotte ^a   De Bruyne, Pauline ^a   Evans, Jonathan ^b   Eggert, Paul ^c   Lottmann, Henri ^d   Norgaard, Jens Peter ^e   Vande Walle, Johan ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e Ferring Phamaceuticals   (Denmark)

Author keywords

Children; Desmopressin; Enuresis; Safety; Tablet

Indexed keywords

DESMOPRESSIN; ANTIDIURETIC AGENT; ARGIPRESSIN[1 DEAMINO]; TABLET;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BODY MASS; CHILD; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; NOCTURNAL ENURESIS; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SKIN DISEASE; TABLET; THORAX DISEASE; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIDIURETIC AGENTS; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; DEAMINO ARGININE VASOPRESSIN; FEMALE; HUMANS; MALE; NOCTURNAL ENURESIS; PROSPECTIVE STUDIES; SYMPTOM ASSESSMENT; TABLETS; TREATMENT OUTCOME;

EID: 84919846498     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0173-1     Document Type: Article

References (18)

1. Hjalmas K, Arnold T, Bower W, et al. Nocturnal enuresis: an international evidence based management strategy. J Urol. 2004;171(6 Pt 2):2545–61.
2. Neveus T, Eggert P, Evans J, et al. Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children’s Continence Society. J Urol. 2010;183(2):441–7.
3. Glazener CM, Evans JH, Peto RE. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev. 2005;2:CD002911.
4. Neveus T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children’s Continence Society. J Urol. 2006;176(1):314–24.
5. Vande Walle J, Rittig S, Bauer S, et al. Practical consensus guidelines for the management of enuresis. Eur J Pediatr. 2012;171(6):971–83.
6. Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2002;3:CD002112.
7. Djurhuus JC, Norgaard JP, Rittig S. Monosymptomatic bedwetting. Scand J Urol Nephrol Suppl. 1992;141:7–17 (discussion 8–9).
8. Van de Walle J, Van Herzeele C, Raes A. Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues. Drug Saf Int J Med Toxicol Drug Exp. 2010;33(4):261–71.
9. Robson WL, Leung AK, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol. 2007;178(1):24–30.
10. VandeWalle J, Stockner M, Raes A, Norgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007;2(3):232–8.
11. Robson WL, Norgaard JP, Leung AK. Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Eur J Pediatr. 1996;155(11):959–62.
12. Lucchini B, Simonetti GD, Ceschi A, et al. Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review. J Pediatr Urol. 2013;9(6 Pt B):1049–53.
13. Dehoorne JL, Raes AM, van Laecke E, Hoebeke P, Vande Walle JG. Desmopressin toxicity due to prolonged half-life in 18 patients with nocturnal enuresis. J Urol. 2006;176(2):754–7 (discussion 7–8).
14. De Guchtenaere A, Raes A, Vande Walle C, et al. Evidence of partial anti-enuretic response related to poor pharmacodynamic effects of desmopressin nasal spray. J Urol. 2009;181(1):302–9 (discussion 9).
15. Lottmann H, Baydala L, Eggert P, et al. Long-term desmopressin response in primary nocturnal enuresis: open-label, multinational study. Int J Clin Pract. 2009;63(1):35–45.
16. Van Herzeele C, Alova I, Evans J, et al. Poor compliance with primary nocturnal enuresis therapy may contribute to insufficient desmopressin response. J Urol. 2009;182(4 Suppl):2045–9.
17. Juul KV, Klein BM, Sandstrom R, Erichsen L, Norgaard JP. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol. 2011;300(5):F1116–22.
18. De Bruyne P, De Guchtenaere A, Van Herzeele C, et al. Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis. Eur J Pediatr. 2014;173(2):223–8.